ATLASGain Therapeutics (GANX) earnings date: Nov 11, 2026
Gain Therapeutics (GANX) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026. Analysts expect EPS of -$0.13.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on GANX
| Last price | $1.13 (0.0%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.3% |
| Earnings beat history | Beat the EPS estimate in 5 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Gain Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Gain Therapeutics reports on Nov 11, 2026. One email the day before, with ATLAS’s read on Gain Therapeutics. You can switch it off at any time.
Alert me before GANX reportsFree to start. Creating an account takes under a minute.
Notify me when Gain Therapeutics reports
Track GANX free Add Gain Therapeutics to a free ATLAS watchlist and see its next report date in one place.
GANX earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.13 |
| Last report | Aug 25, 2026 · Beat |
| Beat rate (last 5 reports) | 5 of 5 (100%) |
| Average EPS surprise | +14.9% |
| Average move around a report | ±7.4% (last 5) |
| Sector | Healthcare · Biotechnology |
Gain Therapeutics earnings history: last 5 reports
Gain Therapeutics last reported on Aug 25, 2026: EPS of $1.06 against an estimate of $0.94 (+12.8% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 25, 2026 | $0.94 | $1.06 | +12.8% | Beat | -9.5% |
| Aug 11, 2026 | -$0.15 | -$0.11 | +26.7% | Beat | +19.8% |
| May 11, 2026 | -$0.14 | -$0.13 | +7.1% | Beat | -1.1% |
| Mar 26, 2026 | -$0.14 | -$0.11 | +21.4% | Beat | -6.6% |
| Mar 19, 2026 | $0.16 | $0.17 | +6.3% | Beat | 0.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for GANX
See the fair value, the probability range and the earnings history of Gain Therapeutics on its ATLAS page.
Gain Therapeutics (GANX) stock analysisPlans from €3.99 a month.
Gain Therapeutics earnings: frequently asked questions
When does Gain Therapeutics (GANX) report earnings?
Gain Therapeutics is scheduled to report on Wednesday, November 11, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for GANX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.13 per share (USD). Estimates can change before the report.
How often does GANX beat earnings estimates?
Of its last 5 reports with a recorded result, Gain Therapeutics beat the EPS estimate 5 times; the average surprise was +14.9%. Past results do not predict the next one.
How much does GANX move around earnings?
Over its last 5 reports the stock moved an average of 7.4% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Gain Therapeutics beat earnings estimates last quarter?
Gain Therapeutics last reported on Aug 25, 2026: EPS of $1.06 against an estimate of $0.94 (+12.8% surprise), a beat.
How much does GANX usually move in a day?
On a normal trading day the ATLAS model puts GANX’s one-day range at about ±4.3%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer